|
Chemical compound
Pharmaceutical compound
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by Pfizer Inc.
References
|
|---|
| Type I | | ALK1 (ACVRL1) | |
|---|
| ALK2 (ACVR1A) | |
|---|
| ALK3 (BMPR1A) | |
|---|
| ALK4 (ACVR1B) | |
|---|
| ALK5 (TGFβR1) | |
|---|
| ALK6 (BMPR1B) |
- Agonists: BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
- Dibotermin alfa
- Eptotermin alfa
- GDF (5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 15)
- Radotermin
|
|---|
| ALK7 (ACVR1C) | |
|---|
|
|---|
| Type II | | TGFβR2 | |
|---|
| BMPR2 | |
|---|
| ACVR2A (ACVR2) |
- Agonists: Activin (A, B, AB)
- BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
- Dibotermin alfa
- Eptotermin alfa
- GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 11 (BMP11), 15)
- Myostatin (GDF8)
- Nodal
- Radotermin
|
|---|
| ACVR2B |
- Agonists: Activin (A, B, AB)
- BMP (2, 4, 6, 7)
- Dibotermin alfa
- Eptotermin alfa
- GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12))
- Myostatin (GDF8)
- Nodal
- Osteogenin (BMP3, BMP3A)
- Radotermin
|
|---|
| AMHR2 (AMHR) | |
|---|
|
|---|
| Type III | |
|---|
| Unsorted | |
|---|
|
